These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 1688611)
21. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456 [TBL] [Abstract][Full Text] [Related]
22. Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen. Misko IS; Schmidt C; Honeyman M; Soszynski TD; Sculley TB; Burrows SR; Moss DJ; Burman K Clin Exp Immunol; 1992 Jan; 87(1):65-70. PubMed ID: 1370774 [TBL] [Abstract][Full Text] [Related]
23. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. Pepperl S; Benninger-Döring G; Modrow S; Wolf H; Jilg W J Virol; 1998 Nov; 72(11):8644-9. PubMed ID: 9765404 [TBL] [Abstract][Full Text] [Related]
28. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Gavioli R; De Campos-Lima PO; Kurilla MG; Kieff E; Klein G; Masucci MG Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5862-6. PubMed ID: 1321426 [TBL] [Abstract][Full Text] [Related]
29. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505 [TBL] [Abstract][Full Text] [Related]
30. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584 [TBL] [Abstract][Full Text] [Related]
31. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972 [TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. Lee SP; Morgan S; Skinner J; Thomas WA; Jones SR; Sutton J; Khanna R; Whittle HC; Rickinson AB Eur J Immunol; 1995 Jan; 25(1):102-10. PubMed ID: 7531142 [TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction. Khanna R; Silins SL; Weng Z; Gatchell D; Burrows SR; Cooper L Eur J Immunol; 1999 May; 29(5):1587-97. PubMed ID: 10359113 [TBL] [Abstract][Full Text] [Related]
34. Cross-recognition of a mouse H-2-peptide complex by human HLA-restricted cytotoxic T cells. Murray RJ; Brooks JM; Rickinson AB; Rowe M Eur J Immunol; 1990 Mar; 20(3):659-64. PubMed ID: 1690661 [TBL] [Abstract][Full Text] [Related]
35. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Khanna R; Burrows SR; Nicholls J; Poulsen LM Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052 [TBL] [Abstract][Full Text] [Related]
36. Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis. Moss DJ; Misko IS; Sculley TB; Apolloni A; Khanna R; Burrows SR Springer Semin Immunopathol; 1991; 13(2):147-56. PubMed ID: 1724100 [No Abstract] [Full Text] [Related]
37. Oligopeptide induction of a secondary cytotoxic T-cell response to Epstein-Barr virus in vitro. Schmidt C; Burrows SR; Moss DJ; Sculley TB; Misko IS Scand J Immunol; 1991 Apr; 33(4):411-20. PubMed ID: 1708166 [TBL] [Abstract][Full Text] [Related]
38. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783 [TBL] [Abstract][Full Text] [Related]
39. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein. Turcanová V; Höllsberg P J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767 [TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis. Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]